Optimized expression of HPV 45 L1 in yeast

Details for Australian Patent Application No. 2004277934 (hide)

Owner Merck & Co., Inc.

Inventors Schultz, Loren D.; Bryan, Jaine T.; Jansen, Kathrin U.; Brownlow, Michelle K.

Agent Spruson & Ferguson

Pub. Number AU-B-2004277934

PCT Pub. Number WO2005/032586

Priority 60/506,812 29.09.03 US

Filing date 24 September 2004

Wipo publication date 14 April 2005

Acceptance publication date 17 September 2009

International Classifications

C12N 15/37 (2006.01) Mutation or genetic engineering

C07K 14/025 (2006.01) Peptides having more than 20 amino acids

A61K 39/00 (2006.01) Medicinal preparations containing antigens or antibodies

Event Publications

6 April 2006 PCT application entered the National Phase

  PCT publication WO2005/032586 Priority application(s): WO2005/032586

17 September 2009 Application Accepted

  Published as AU-B-2004277934

21 January 2010 Amendment Made

  The nature of the amendment is: Amend the Patentee from Merck & Co., Inc. to Merck Sharp & Dohme Corp.

21 January 2010 Standard Patent Sealed

11 October 2012 Alteration of Name

  The name of the patentee has been altered to Merck Sharp & Dohme Corp.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2004277939-Method and devices to replace spinal disc nucleus pulposus

2004277932-Phenyl pyrrolidine ether tachykinin receptor antagonists